Clinical Trial Update: Velcade and Sorafenib in Unresected or Metastatic Renal Cell Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating Velcade (bortezomib) with sorafenib in unresected or metastatic renal cell carcinoma was terminated; results were posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Nexavar (Sorafenib)
• Velcade (bortezomib)

Snippet

Sponsor: New Mexico Cancer Research Alliance | Conditions: Metastatic Renal Cell Carcinoma | Phase 2 | Status: TERMINATED | Results posted: 2015-09-17